ArticleScientific reports2019
Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- The glycobiology of prostate cancer: an update.Oncogene · 2026Review
- High-MannoseJournal of proteome research · 2026Article
- Integrative analysis reveals PRKCB and SRD5A2 as potential immune-associated biomarkers in prostate cancer targeted by traditional Chinese medicine.Frontiers in oncology · 2026Article
- A multi-analyte liquid biopsy approach for nonseminomatous testicular germ cell tumors: combining cfDNA and N-glycan analysis in blood and seminal plasma.Cancer cell international · 2025Article
- AI for BPH Surgical Decision-Making: Cost Effectiveness and Outcomes.Current urology reports · 2024Review
- Multimodal data integration for predicting progression risk in castration-resistant prostate cancer using deep learning: a multicenter retrospective study.Frontiers in oncology · 2024Article
- Mouse tissue glycome atlas 2022 highlights inter-organ variation in major N-glycan profiles.Scientific reports · 2022Article
- Alteration of rhesus macaque serum N-glycome during infection with the human parasitic filarial nematode Brugia malayi.Scientific reports · 2022Article
- Machine learning diagnosis by immunoglobulin N-glycan signatures for precision diagnosis of urological diseases.Cancer science · 2022Article
- Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.BMC cancer · 2022Article
- N-glycan Characterization by Liquid Chromatography Coupled with Fluorimetry and Mass Spectrometry.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.World journal of urology · 2021Article
- Imidazolium labelling permits the sensitive mass-spectrometric detection ofChemical communications (Cambridge, England) · 2021Article
- Glycan Imaging Mass Spectrometry: Progress in Developing Clinical Diagnostic Assays for Tissues, Biofluids, and Cells.Clinics in laboratory medicine · 2021Review
- Narrative review of urinary glycan biomarkers in prostate cancer.Translational andrology and urology · 2021Review
- N-glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas.Cancer medicine · 2021Article
- Associations Between Genetically Predicted Plasma N-Glycans and Prostate Cancer Risk: Analysis of Over 140,000 European Descendants.Pharmacogenomics and personalized medicine · 2021Article
- Machine Learning Based Analysis of Human SerumCancers · 2020Article
- Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-ThroughputInternational journal of molecular sciences · 2020Article
- Analysis of serum glycome by lectin microarrays for prostate cancer patients - a search for aberrant glycoforms.Glycoconjugate journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the diagnostic and prognostic potential of serum N-glycan profiling for castration-resistant prostate cancer (CRPC). We retrospectively investigated serum N-glycan structural analysis by glycoblotting for 287 patients with benign prostatic hyperplasia (BPH), 289 patients with newly diagnosed prostate cancer (PC), 57 patients with PC treated with androgen-deprivation therapy without disease progression (PC-ADT), and 60 patients with CRPC. N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The CRPC N-glycan score could classify CRPC patients with sensitivity, specificity, and area under the curve of 87%, 69%, and 0.88, respectively. The CRPC N-glycan score >1.7 points was significantly associated with poor prognosis in patients with CRPC. The glycoprotein analysis showed that not immunoglobulins but α-1-acid glycoprotein (AGP) were a potential candidate for the carrier protein of N-glycans. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.